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Abstract: Systemic allergic reactions to insect stings affect up to 5% of the population during 
their lifetime, and up to 32% of beekeepers. Such reactions can be fatal, albeit very rarely, and 
fear of a further systemic reaction (SR) can lead to significant anxiety and quality of life impair-
ment. A recent Cochrane systematic review confirmed that venom immunotherapy (VIT) is an 
effective treatment for people who have had a systemic allergic reaction to an insect sting. VIT 
reduces risk of a further SR (relative risk 0.10, 95% confidence interval 0.03–0.28), but VIT 
also reduces risk of a future large local reaction, and significantly improves disease-specific 
quality of life. However, health economic analysis showed that VIT is generally not cost effec-
tive for preventing future SRs; most people are stung infrequently, most SRs resolve without 
long-term consequences, and a fatal outcome is extremely rare. VIT only becomes cost effective 
if one is stung frequently (eg, beekeepers) or if quality of life improvement is considered. Thus, 
for most people with insect sting allergy, anxiety and quality of life impairment should be the 
overriding consideration when making treatment decisions, highlighting the importance of a 
patient-centered approach. Areas which need to be explored in future research include efforts 
to improve the safety and convenience of VIT such as the use of sublingual immunotherapy; 
quality of life effects of venom allergy in children and adolescents as well as their parents; and 
the optimal duration of treatment.
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Background
A variety of stinging insects can cause allergic reactions in humans. The most common 
are: wasps (hornets [Vespa], yellow jackets [United States]/wasps [Europe] [Vespula], 
paper wasp [Polistinae]), bees (honey [Apis mellifera], bumble bees [Bombus]), 
and stinging ants (fire ants [Solenopsis], jack jumper and bull ants [Myrmecia], and 
Pachycondyla).1 Their taxonomy is shown in Figure 1. Venom from the jack jumper 
ant is the most allergenic of the venoms and causes the highest rate of anaphylaxis.1 
Honeybee stings are also generally held to be more severe than wasp stings. Bees inject 
50–140 µg of venom.2,3 Due to a unique barbed stinging apparatus, the bee stinger is 
often still attached, and venom can continue to be injected for up to 1 minute follow-
ing removal of the insect. However, bees cannot sting again, whereas wasps can sting 
multiple times delivering ∼3 µg of venom with each sting.1 Wasps are aggressive and 
sting to attack, whilst bees sting as a defensive maneuver. Most reactions manifest as 
a painful, erythematous swelling at the sting site.
Whilst most sting reactions are painful and annoying, they are easily dealt with 
and resolve quickly. Unfortunately, some people react more vigorously to stings 
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and in such a way that requires treatment. This can be as a 
large local reaction (LLR) (.10 cm diameter), thought to 
represent a late-phase IgE mediated allergic reaction. This 
can sometimes be mistaken as cellulitis as it can last up to 
24–48 hours.5 Reactions which cause symptoms beyond the 
local site of sting are termed systemic reactions (SRs). Severe 
life-threatening SRs (anaphylaxis) can occur, and are termed 
venom anaphylaxis. If a patient experiences a LLR, there is 
5%–10% risk of them developing a systemic allergic reaction 
to a sting in the future.5–7
Anaphylaxis to an insect sting is classified not only on 
the basis of cardiac or respiratory compromise, but also by 
any abdominal cramps or vomiting. This is unlike allergic 
reactions to food where gastrointestinal symptoms can be 
part of nonanaphylactic reactions, since the gastrointestinal 
tract is the site of allergen exposure.8 Anaphylaxis to an 
insect sting can cause a terrifyingly rapid death, with initial 
cardiorespiratory arrest within 5–10 minutes of the sting in 
many such cases.9 The possibility of such an event can lead 
to significant anxiety and social restrictions in people at risk 
of an allergic reaction to an insect sting.
Prevalence and incidence  
of venom allergy
Hypersensitivity to insect stings affects up to 5%–7.5% of the 
population and up to 32% of beekeepers.10 If a sting reaction 
is classified as anaphylaxis, the risk of anaphylaxis with a 
future sting is significantly raised, but is still less than 50% 
in most cases. The risk is greater in those with more severe 
previous venom anaphylaxis, and lower in children.1,11
The rates of venom allergy leading to hospital admission 
for anaphylaxis have risen since 1992.12 Venom anaphylaxis 
admissions appear to be increasing in the UK at a rate of 
11.5% (95% confidence interval [CI] 10.4–12.7) per year, 
in keeping with other forms of anaphylaxis.12 However, fatal 
reactions are not increasing; the increase in admissions may 
be due to changes in awareness, health-seeking behavior, or 
coding. Hospital admission for venom anaphylaxis is very 
rare in the first 3 decades of life and rises with increasing 
age. Ninety-three episodes of fatal venom anaphylaxis 
occurred in the UK over a 10-year period at a mean age 
of 59 years, which converts to a fatality rate of 0.009 per 
100,000 population per annum.12 In the US, at least 40 people 
per year die from insect stings.13 Overall, fatalities from sting 
anaphylaxis range from 0.03 to 0.48 per million inhabitants 
per year. Fatal venom anaphylaxis accounts for 20% of all 
anaphylaxis fatalities.14
Whilst this mortality rate is important and anaphylaxis is 
relatively common, it is interesting to note that severe immedi-
ate outcomes are rare, with only 2% of significant anaphylaxis 
involving cardiorespiratory arrest.15 Long-term morbidity 
following venom anaphylaxis has not to our knowledge been 
reported beyond the psychological consequences of venom 
allergy. Insect stings can also be fatal without leading to an 
allergic reaction, especially if multiple stings are delivered.16 
SRs are more likely in men, older patients, patients with a 
raised baseline tryptase level,17,18 those taking angiotensin-
converting-enzyme (ACE) inhibitors17,18 or beta blockers,19 and 
with physical exercise around the time of the sting, eosino-
philia,20 or nonsteroidal anti-inflammatory drug ingestion.21
 Hymenoptera
Ant
Formicidae
Myrmicinae
Myrmecia Solenopsis
Vespinae
Vespa Vespula Dolichovespula Polistes
Polistinae
Apis
mellifera
Bombus
terrestris
BombusApis
Apinae
Apoidea
Apoidea
BeeWasp
Vespoidea
Vespidae
Figure 1 Modified taxonomic tree of stinging insects.
Notes: Data from Tan and Campbell1 and Krishna et al.4
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The life-time prevalence of an allergic reaction to stings in 
adults in America is documented as 19% via a self-reported 
telephone survey.22 Of these patients, a previous allergic 
reaction to any substance raised the life-time prevalence of 
venom allergy to 41%, nearly 20% of whom had confirmed 
anaphylaxis. European data (NORA)15 found that 20% of 
documented anaphylaxis was due to venom allergy in the 
European pediatric population. In adults, venom as the 
cause of anaphylaxis was 48.2%. Of these, 70.6% of stings 
were caused by wasps, 23.4% bee, and 4.1% hornet venom. 
Data for the UK show venom to be a less common cause of 
anaphylaxis: accounting for ∼10% of hospital admissions for 
anaphylaxis at all ages, and very few cases in children.12
Diagnosis of venom allergy
Diagnosis of any allergic reaction requires a clear, thorough 
medical history. However, in hymenoptera venom allergy, 
difficulty can occur in ascertaining the type of insect sting.23 
The issue is also clouded as the sensitization rate (positive 
tests to hymenoptera venom but with a negative history) is 
quite high; 25%–50% of people with positive specific IgE 
(sIgE) or intradermal tests for venom and a positive history 
of insect sting reaction have a positive sting challenge.24 
However, people with a clear documented history of a venom 
reaction can have negative tests, and occasionally testing can 
be positive to both honey bee and wasp venom.4
Allergy skin testing
Skin prick testing (SPT) and intradermal testing should be 
performed at least 2 weeks after a sting reaction, ideally 
1–2 months later in case of false negatives due to a refrac-
tory period after a sting. However, the sensitivity of SPT is 
lower than that of intradermal testing. Increasing doses of 
venom traditionally have been used for either SPT or intra-
dermal testing; initially performed at low concentrations, 
the level of venom is increased until a positive reaction is 
exhibited.25 The SPT should be performed at a concentra-
tion between 1.0 and 100 µg/mL, and the intradermal initial 
concentration should be in the range of 0.001–0.01 µg/mL. 
It should then increase in tenfold increments to a maximum 
concentration of 1.0 µg/mL.17 Recent information26 suggests 
that simultaneous intradermal testing with different venoms 
is safe and efficient.
sige testing
In vitro sIgE testing for wasp and bee allergens can supple-
ment the clinical history and skin testing. The sensitivity of 
venom sIgE, as for other allergens, is generally lower than that 
of skin (intradermal) testing. sIgE can be performed for the 
whole extract or for components in the venom. These compo-
nents can be natural components (nApi m 4) or recombinant 
allergens (rApi m 1, rVes v 1, rVes v 5, rPol d 5).27 The use of 
natural venom extracts can lead to clouding of the diagnostic 
process secondary to cross-reacting carbohydrate determi-
nants (CCDs). Recombinant allergens can circumnavigate 
the issues of: double-positive tests to bee and wasps with 
an unclear history; patients with a negative test but a good 
clinical history where natural allergens may have degraded 
or denatured; and planning of immunotherapy. Commercially 
available microarray chips can measure multiple components 
at once, including rApi m 1, nApi m 4, rPol d 5, and rVes 
v 5, to aid in venom allergy diagnosis.28 There is strong 
immunological cross-reactivity between species: between 
honey bee and wasp there is 50% sequence homology in the 
hyaluronidase enzymes.29 Api m 2 and Ves v 2 (hyaluroni-
dases), and Api m 5 and Ves v 3 (dipeptidyl-peptidases), are 
well-known to cross react.30 This cross-reactivity is mainly 
due to CCDs exhibited in both allergen pairs,31 though they 
also show protein cross-reactivity. CCD-free components for 
in vitro diagnostic testing are Api m 1, Pol d 1 and 5, and Ves 
v 1 and 5. The venom from bees and wasps contains many 
different components. A list of the major venom allergens 
from honey bees, bumble bees, and the main wasp species 
is shown in Table 1.
The major honeybee allergen is Api m 1, but unfortu-
nately this has been shown to have low sensitivity,33 though 
the sensitivity can alter due to the criteria of the patient 
population studied. In wasp-allergic patients, rVes v 5 has 
good diagnostic performance.30 If used in conjunction with 
Ves v 1, the sensitivity was significantly increased.34 The 
most reliable serological indicators to aid in diagnosis of 
true double-sensitization or cross-reactivity in patients with 
positive IgE results to both venom extracts are Api m 1 and 
Ves v 5.35 In patients who are positive to both Polistes and 
Vespula, the use of Pol d 5 and Ves v 5, and Pol d 1 and Ves 
v 1 can be discriminatory.36
Basophil activation test
Evidence is increasing that basophil activation tests can 
be used to discriminate clinical reactivity, and severity of 
clinical reactivity, in allergic disorders.37,38 With regard to 
venom allergy, one study39 suggested that basophil activation 
tests can be useful in the setting of negative intradermal test 
results to complement sIgE testing when the latter is positive. 
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Another study suggested basophil activation tests may be 
useful for aiding the decision to cease immunotherapy.40 The 
emerging role of basophil activation tests in the diagnosis and 
management of venom allergy requires further study.
Treatment of venom allergy
Acute treatment of venom  
allergic reactions
Acute treatment of allergic reactions to venom involves local 
care for LLRs including cold packs, antihistamines, NSAID 
gels, analgesia, or systemic corticosteroids as appropriate. 
SRs to venom are managed in the same way as other triggers 
of systemic allergic reactions. However, the rapid onset of 
venom allergic reactions, and the association with cardio-
vascular compromise, especially hypotension, mean that 
aggressive treatment with oxygen, intravenous fluids, and 
adrenaline needs to be started early.41,42 Appropriate posture 
may also be an important way of preventing adverse cardiac 
outcomes during a venom allergic reaction.43 Emergency 
department studies suggest that low-dose peripheral 
adrenaline infusion may be the optimal way to manage 
venom anaphylaxis, and such infusions may need to be 
continued for many hours.44 Older studies suggest that bolus 
adrenaline, even when administered intravenously, may 
have very limited and transient effects on cardiovascular 
parameters when used to treat venom anaphylaxis.45 For 
bee stings, removal of the sting may reduce the total dose 
of venom and is an important part of first aid management – 
there is no clear evidence that any specific method for sting 
removal is superior.46
Long-term management following a 
systemic venom allergic reaction
Following recovery from an acute SR to an insect sting, 
provision of an adrenaline auto-injector is recommended47 
although this has not been shown to improve quality of 
life.48 Other advice may include avoidance of high-risk 
activities/locations, methods for removal of stings should 
there be further insect stings,46 and provision of antihista-
mine, bronchodilator medication, and corticosteroids. For 
the purpose of this review, we will focus our discussion 
on the role of venom immunotherapy (VIT) for prevention 
of further allergic reactions to insect stings and promot-
ing improved quality of life in those with a past history of 
significant reaction.
History of viT
Allergen immunotherapy for hay fever was discovered at 
St Mary’s Hospital in London by Leonard Noon in 1911, 
and the first randomized controlled trial of this treatment 
for hay fever, also at St Mary’s Hospital, proved its efficacy 
in 1954.49,50 The first report of VIT was described in 1925,51 
where the whole crushed body of a wasp was used. Whole-
body extract VIT continued to be used for many years52 until 
it was shown to be ineffective in a randomized controlled 
trial. It was not until 1978 that an effective modality of VIT 
was developed. This used venom extracted from venom 
sacs, and was shown to be highly effective in a randomized 
controlled trial.53 Since that time, extracted venom has been 
used for immunotherapy with wasps, hornets, jumper ants, 
and honey bees. However, for fire ants, whole-body extract 
is still used in the US, and the latter practice has not yet been 
subjected to a randomized controlled efficacy trial.
In VIT, gradually increasing doses of insect venom are 
administered to induce immunological tolerance, typically 
by subcutaneous injection at an interval of several weeks for 
up to 5 years. Extrapolating from randomized controlled trial 
Table 1 Hymenoptera venom allergens
Venom Allergen Common name
Apis mellifera (honey bee) Api m 1 Phospholipase A2
Api m 2 Hyaluronidase
Api m 3 Acid phosphatase
Api m 4 Melittine
Api m 5 Allergen C
Api m 6 Protease inhibitor
Api m 7 Protease
Api m 8 Carboxylesterase
Api m 9 Carboxylesterase
Api m 10 CRP
Api m 11.0101 MRJP8
Api m 11.0201 MRJP9
Api m 12 vitellogenin
Bombus pennsylvanicus  
(bumble bee)
Bom p 1
Bom p 4
Phospholipase A2
Serine protease
Vespula vulgaris (wasp) ves v 1 Phospholipase A1
ves v 2.0101 Hyaluronidase
ves v 2.0201 Hyaluronidase
ves v 3 DPP iv
ves v 5 Antigen 5
ves v 6 vitellogenin
Polistes annularis (American  
paper wasp)
Pol a 1 Phospholipase A1
Pol a 2 Hyaluronidase
Pol a 5 Antigen 5
Polistes dominula (european  
paper wasp)
Pol d 1 Phospholipase A1
Pol d 4 Protease
Pol d 5 Antigen 5
Notes: Data from Spillner et al.32 Adapted with permission from John wiley and 
Sons. Biló BM, Rueff F, Mosbech H, Bonifazi F, Oude-elberink JN; the eAACi interest 
Group on insect venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. 
Allergy. Copyright (c) 2005 Blackwell Munksgaard 2005.8
Abbreviations: CRP, carbohydrate rich protein; MRJP, major royal jelly protein.
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evidence in relation to hay fever, a treatment course of 3 years 
is recommended, although longer courses are recommended 
in some settings.4,54
Immunotherapy works through complex immunological 
mechanisms. The initial mechanism of action is a mast cell 
and basophil desensitization, followed by changes in T-cells 
(including the formation of T regulatory cells to the allergen) 
and finally an alteration in B-cell, IgE (an initial rise, followed 
by a reduction over several months), mast cell, basophil, and 
eosinophil responses to the allergen.55,56 Monitoring during 
VIT has shown a drop in sIgE and a rise in IgG4.57–59 These 
immunological changes can be seen in Figure 2.
viT treatment protocols
VIT is commercially available for honeybee, paper wasp, 
and yellow jacket (“European”) wasps since these are the 
commonest causes of venom anaphylaxis worldwide. To our 
knowledge, immunotherapy products for ant allergy are not 
currently commercially available. This review will therefore 
focus on wasp and honeybee VIT using extracted venom. At 
present, the treatment offered for venom allergy is largely 
via subcutaneous immunotherapy (SCIT). Treatment regimes 
are diverse and the populations they have been tested on 
vary. This makes comparison between schedules difficult. 
However, the ability to tailor the schedule to each patient 
will improve efficacy and optimize safety.10 Up-dosing 
treatment protocols for subcutaneous VIT can be divided into 
roughly four groups which are summarized in Table 2.10,60–62 
In general, rapid up-dosing is more convenient for patients 
but carries increased risk of a systemic allergic reaction to 
treatment.
Improvement of honeybee immunotherapy efficacy may 
be possible by increasing the quantities of major determinants 
such as Api m 3 and 10 in VIT preparation, or tailoring the 
allergenic component mix according to individual patient 
sensitization pattern. This could be done by improving the 
method of generating the venom preparation, spiking the 
venom with recombinant allergens, or tailoring the immu-
notherapy for different patients with a range of component 
allergens relevant for that patient.32,63,64
VIT starting doses are often around 0.0001 µg per injec-
tion and rise to a maintenance does of 100 µg (approximately 
two bee stings or 30 wasp stings). In children, data from a 
small study suggest that a lower 50 µg maintenance dose 
provides effective protection from SRs with potentially 
improved safety profile.65 Longer induction-phase treatments 
can be done as an outpatient; however, for rush therapy, hos-
pital admission is advisable. Although the safety profile of 
semi-rush and ultra-rush VIT up-dosing protocols is good,60,62 
in general, accelerated up-dosing immunotherapy protocols 
are associated with increased risk of systemic allergic reac-
tion to VIT.17
Switch from Th2 to Th1 and T reg Inhibition via IL-10, TGF-β, IFN-γ, CTLA-4
IFN-γ
IgG and IgG4 IgA IgE
Decrease in levelsIncrease in levels
Inhibition via IL-10
IL-10, TGF-β
IL-10 TGF-β
T reg
IL-4, IL-13 IL-3, IL-5, IL-9
Th0
Th1
B-cell B-cell B-cell
Eosinophi Basophil Mast cell
Th2
Figure 2 immunological changes in immunotherapy.
Note: Early (4–12 weeks) changes include the induction of allergen-specific T regs. Longer-term, there is an increase in inhibitory IgG4. This final change appears to be the 
key for long-term tolerance induced by subcutaneous immunotherapy or sublingual immunotherapy.
Abbreviations: CTLA-4, cytotoxic T-lymphocyte-associated protein 4; iL, interleukin; iFN-γ, interferon gamma; ig, immunoglobulin; TGF-β, transforming growth factor 
beta; Th, T helper cells; T reg, regulatory T-cells.
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The maintenance dose interval has historically been set 
at 1 month but studies have shown that intervals of up to 
3–4 months retain their efficacy.66 In patients who experience 
SRs to stings during the traditional regime induction, accel-
erated induction protocols have been successfully used.67 If 
a patient experiences a SR during maintenance VIT then a 
larger dose of 200 µg can be given, although switching to 
a lower maintenance dose for a prolonged period may be 
needed first.68
Patient selection for viT
VIT is recommended “as an option for the treatment of 
IgE-mediated bee and wasp venom allergy”.69 However, 
guidelines vary in suggested indications for VIT. We pres-
ent a summary of the major international guidelines for 
patient selection for VIT in Table 3. There is significant 
inconsistency between guidelines, especially in relation to 
patients with a history of less severe local reactions or SRs. 
There are variations in the relative role of attempts at risk 
stratification through frequency of stings/severity of incident 
reaction versus focusing on the quality of life impact of the 
allergy on patients when making treatment decisions. We will 
discuss these specific issues below, because recent findings 
shed some light on considerations to be made during patient 
selection for VIT, and suggest the need for revised and more 
consistent patient-selection guidance.
Recommendations for VIT patient selection from the 
European Academy of Allergy and Clinical Immunology 
(EAACI); American Academy of Allergy, Asthma and 
Immunology (AAAAI); National Institute for Health and 
Care Excellence (NICE); and the British Society of Allergy 
and Clinical Immunology (BSACI) are listed in Table 3.
Contraindications for VIT also vary between guidelines. 
Manufacturer-stated contraindications for Pharmalgen 
(ALK-Abelló, Horsholm, Denmark) include malignancy, 
severe asthma, immunological conditions, chronic heart and 
lung disease, severe hypertensions, beta blockers, tricyclic 
antidepressants, monoamine oxidase inhibitors, angiotensin-
converting enzyme inhibitors, and initiation during pregnancy 
(though maintenance can be continued in pregnancy).69
Efficacy of VIT: reduction in SRs
In the recent Cochrane systematic review, VIT was shown 
to significantly reduce risk of SR to a future sting in people 
who have already suffered at least one SR to a sting (rela-
tive risk [RR] 0.10, 95% CI 0.03–0.28).17 From the seven 
trials (392 participants) included in the Cochrane review, 
2.7% of patients post-VIT had a systemic allergic reaction 
on re-sting, compared to 39.8% untreated.19 The review 
included both adults and children, allergic to bee, wasp, 
or ant venom, and follow-up varied from months to years 
with re-stings triggered by either accidental field stings or 
intentional supervised sting challenges. One trial used sub-
lingual (SLIT) and six trials used subcutaneous VIT, with 
little evidence of difference in treatment outcomes. VIT is 
the only specific treatment for venom allergy which can 
provide a reduction in morbidity. Mortality is so rare that 
proving VIT reduces mortality is a challenging task; how-
ever, the Cochrane review found VIT was effective across 
the range of reaction severity suggesting that it is likely to 
reduce risk of fatal venom anaphylaxis as well as nonfatal 
venom anaphylaxis.
The effectiveness of VIT is apparent immediately once the 
maintenance dose is reached.14 One study suggested a 10% 
reaction risk for each sting post-cessation of treatment, with 
a cumulative risk of a SR reaching a plateau of 20% after a 
decade posttreatment cessation.71 In patients not responding 
to VIT, it has been found that basophil activation test response 
to venom in vitro is associated with treatment efficacy. In 
patients who reacted to venom stings after completing VIT, 
they were found to have higher basophil responses than those 
who tolerated stings post-VIT.72
Efficacy of VIT: reduction in LLRs
The Cochrane review also found that VIT significantly reduces 
the risk of a LLR from venom (RR 0.41, 95% CI 0.24–0.69).19 
Both SCIT and SLIT VIT are effective in reducing LLRs as 
well as SRs.19 The role of VIT for LLRs is controversial, given 
the relatively low risk of serious outcomes with future stings in 
those with a history of LLRs. Those with troublesome recur-
rent LLRs, or associated anxiety or quality of life impairment 
through concern about further LLRs or SRs, may be considered 
for VIT. Although VIT is not indicated for LLRs in the EAACI 
and BSACI guidelines, they are cited as a relative indication 
in the AAAAI practice parameter (Table 3).
Table 2 Typical viT up-dosing protocols
Duration of  
up-dosing
Dosing interval
Traditional/slow/
conventional
4–6 months 3–7 days
Semi-rush 8 weeks
Rush 2–3 weeks 2 hours
Ultra-rush 120 minutes to 2 days 20 minutes to 2 hours
Cluster/modified 
rush
6 weeks 30 minutes to 2 injections 
every 3–7 days
Abbreviation: viT, venom immunotherapy.
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Efficacy of VIT: quality of life
Allergy to insect venom has been documented to cause 
emotional distress in patients leading to a decrease in their 
quality of life.73 VIT has been shown to improve the qual-
ity of life of people undergoing therapy above and beyond 
those who simply carry an adrenaline auto-injector (using a 
seven-point score where a score of 1–3 gave a positive view 
of treatment). The study found that patients with previous 
anaphylaxis had a more positive view of life after treatment 
(RR 2.01, 95% CI 1.43–2.82), as well as those patients with 
previous cutaneous SR (RR 2.24, 95% CI 1.13–4.43).19 
These differences were seen in women and men, patients 
with varying degrees of baseline anxiety, and those with 
recent stings or stings over 1 year ago.48 It has been quoted 
that 72% of patients undergoing VIT derive benefit in their 
quality of life by undergoing treatment,48 and those who do 
not derive a quality of life benefit are those who have no 
quality of life impairment at baseline (Dr Hanneke Oude-
Elberlink, personal communi cation, January 2015). The 
Cochrane review found that VIT improves venom-specific 
quality of life by a mean 1.21 points (95% CI 0.75–1.67) 
on a seven-point scale19 (where a change of 0.5 points has 
been defined as the minimally important difference).74 There 
is also evidence suggesting that the use of a sting challenge 
during the maintenance phase of VIT, when tolerated, can 
improve quality of life.75,76
Table 3 Patient selection for viT – discrepancies between guidelines
EAACI8 AAAAI17,58 NICE70,* BSACI4
indications Respiratory and 
cardiovascular symptoms 
with positive skin test  
and/or ige 
Urticaria if risk factors or 
quality of life impairment 
present with positive skin 
tests and/or ige
Systemic reaction (especially  
respiratory symptoms,  
cardiovascular symptoms, or both)  
to an insect sting with specific IgE  
to venom allergens 
Previous near-fatal anaphylactic  
reaction to a sting 
Patients with mastocytosis or and  
increased baseline serum tryptase
Severe systemic reaction to  
bee or wasp venom 
Moderate systemic  
reactions with one of the  
following: 
•  Raised baseline serum  
tryptase
•  High risk of future stings
•  Anxiety about future stings
Systemic reaction with 
hypotension ± laryngeal edema ± 
asthma 
Must have positive venom-
specific IgE
Relative  
indications
Adults who experience only  
cutaneous manifestations to an  
insect sting and positive specific IgE  
are generally considered candidates 
for viT, although the need for viT  
in this group is controversial 
Large local reaction to stings  
but have frequent unavoidable  
exposure
Mild asthma, moderate 
angioedema, abdominal pain, 
vomiting, diarrhea, mild 
hypotensive symptoms (light 
headedness, dizziness) in those 
at risk of further stings, eg, 
bee keeper/proximity to bees; 
occupational exposure, eg, fruit 
farmers, gardeners, etc 
Other factors, eg, proximity to 
medical help, patients’ preference, 
effect on quality of life
Contraindications Large local reactions only 
Unusual reactions 
Negative skin tests or ige 
regardless of reaction
Patients who have experienced  
only large local reactions to stings 
viT is generally not necessary in  
children 16 years old and younger  
who have experienced cutaneous  
systemic reactions without other  
systemic manifestations after an  
insect stings
Not usually in cutaneous 
systemic reaction, eg, urticaria ± 
angioedema 
Local reaction 
Toxic reaction 
Any systemic reaction, 
independent of severity if 
negative specific IgE
Risk factors Beta blocker use is a  
relative contraindication  
based on risk
Discontinue ACe inhibitors if  
possible
Comorbid conditions including 
asthma or other respiratory 
disease, cardiac conditions, 
and raised baseline tryptase/
mastocytosis should be carefully 
considered before making a 
decision for viT
Note: *NICE guidance refers to one specific VIT product – Pharmalgen bee and wasp venom immunotherapy (ALK-Abelló, Horsholm, Denmark) – other guidance refers 
to all viT products.
Abbreviations: AAAAi, American Academy of Allergy, Asthma and immunology; ACe inhibitor, angiotensin-converting-enzyme inhibitor; BSACi, British Society of Allergy 
and Clinical immunology; eAACi, european Academy of Allergy and Clinical immunology; ige, immunoglobulin e; NiCe, National institute for Health and Care excellence; viT, 
venom immunotherapy.
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Adverse events associated with VIT
Serum tryptase should be performed on patients undergoing 
VIT to rule out mastocytosis.1 In patients with mastocytosis, 
due to their significant risk of SR even after VIT and risk of 
anaphylaxis from other causes, continued availability of an 
adrenaline auto-injector is recommended following VIT.4 
For all patients, there is a risk of a systemic adverse reaction 
during VIT; 9.3% suffered a SR in the randomized controlled 
trials included in the Cochrane review.19 In a larger series 
of observational studies, the authors found 14.2% of people 
suffered a systemic allergic reaction due to a VIT injection 
for bee venom, and 2.8% for wasp venom.19 NICE estimated 
that the treatment-related adverse reaction rate is 2% per 
injection in the initial phase and 0.26% per injection during 
the maintenance phase.69 Adverse reactions are more likely 
with bee venom VIT, when there is a short time between 
sting and VIT, during up-dosing (initial) phase, in the elderly, 
in those using beta blockers, in clonal mast cell activation 
syndrome, in asthmatic children, and in those with elevated 
serum basal tryptase.10,77,78 Elevated serum tryptase did not 
lead to an increased risk of VIT failure.79
There does, however, seem to be debate about the link 
between length of maintenance treatment and VIT failure 
after a field sting.79,80 VIT failure was more likely to be linked 
to bee venom than wasp (16%–18% versus 4%–7.5%),80,81 
ACE inhibitors, and systemic allergic reaction during dose 
increasing.79 Sting challenges are reputed to historically reveal 
failure of VIT in up to 22% of patients undergoing therapy.82
In the event of an LLR or SR during VIT, the recom-
mendation is to reduce the dose to the last tolerated dose 
with careful dose escalation.4 However, antihistamine given 
pre-injections in traditional, rush, and ultra-rush VIT reduces 
the incidence of local reactions, and may play a role in 
enhancing the efficacy of immunotherapy83–85 and should be 
used in patients who have experienced reactions during VIT. 
There are a small subsection of patients who do not respond 
to VIT at all. There are ongoing studies at present investi-
gating changes in gene expression in relation to response to 
treatment. The belief is that genetic factors may influence a 
patient’s response to VIT and genetics may show the way 
to best tackle this problem.86
Cost-effectiveness of VIT
Bee venom extracts from Pharmalgen (ALK-Abelló) cost 
£54.81 per induction and £15.94 per maintenance injection. Wasp 
induction costs £67.20 and £20.51 per injection during mainte-
nance.69 Whilst the cost varies per protocol, the average cost of 
a full treatment is £2,299.33 per patient.64 Cost-effectiveness of 
Pharmalgen (ALK-Abelló)70 was examined in a NICE health 
technology assessment, in providing VIT for patients who 
have suffered a SR to bee or wasp venom. Four randomized 
controlled trials and five “quasi-experimental” small studies of 
poor quality were found so the authors were unable to perform 
meta-analysis. The clinical evidence suggested that there was a 
decrease in reactions to stings post-immunotherapy, but there 
were associated adverse reactions, some of which were systemic 
although all were treatable. The assessment group developed 
an economic model to compare cost-effectiveness of VIT with 
other treatment options for venom allergy.
In general, they found that VIT is not cost-effective when 
only considering direct costs of outcomes.87 This is because for 
most people, recurrent insect stings are rare, and even in those 
with a history of severe venom allergic reaction previously, the 
risk of fatal outcome following a sting is extremely low. How-
ever, immunotherapy was found to be cost-effective in patients 
at high risk of future stings ($3.3 a year, for people such as bee 
keepers, their neighbors and children, roofers, and gardeners) 
and in those whom the quality of life indices show improvement 
with reduced anxiety. In those at high risk of a future sting (five 
or more stings per year) the incremental cost-effectiveness ratio 
of VIT with an adrenaline auto-injector and high-dose antihista-
mines is £23,368 per QALY (quality adjusted life year) gained 
when compared with high-dose antihistamine and adrenaline 
auto-injector alone, and £25,661 compared to avoidance advice 
only. These findings are summarized in Table 4.
Regarding quality of life impact, even a very small 
improvement in anxiety associated with treatment (0.01 points 
on the EuroQol-5 Dimension Questionnaire [EQ-5D]) makes 
the VIT cost-effective in the base case scenario of one sting 
every 9 years. This suggests that most people with a history of 
insect sting allergic reaction who are concerned enough to seek 
treatment, and are appropriately informed of the prognosis and 
treatment of the condition, merit consideration of VIT. Thus, 
focusing immunotherapy on those who are concerned, those 
Table 4 Summary of Pharmalgen viT health economic 
assessment70
Model Cost per QALY
Base case scenario £18,065,527 (€22,302,132)
Sting frequency $3.3 stings per year Cost savings from viT
Sting frequency 3.1 stings per year £30,000 (€37,000)
Quality of life improvement 0.008 points  
on eD-5Q with viT
£30,000 (€37,000)
Note: A threshold of £30,000 per QALY saved is used by NiCe for approving 
therapies for use within the UK National Health Service.
Abbreviations: eQ-5D, euroQol-5 Dimension Questionnaire; NiCe, National 
institute for Health and Care excellence; QALY, quality-adjusted life year; viT, 
venom immunotherapy.
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who have documented quality of life impairment related to fear 
of future sting reactions, and those who have frequent insect 
stings is at least as important as considerations of individual 
risk for severe reaction based on severity of prior reaction.70
This new information, that quality of life impact is the key 
driver of cost in relation to venom allergy sheds some light 
on the discrepancies seen in the guidelines summarized in 
Table 3. In common with food allergy, the lives of individuals 
with venom allergy are overshadowed by the possibility of 
sudden, unexpected, rapidly fatal anaphylaxis. Such events 
are extremely rare, but fear of them is a major contributor to 
quality of life impairment and, in the case of venom allergy, 
quality of life can be improved by using VIT to reduce the 
risk of such an outcome.
If we refer back to Table 3, it is clear that VIT treatment 
guidelines are making an attempt to “risk stratify” patients 
on the basis that the decision whether or not to treat with VIT 
should be driven by risk of fatal or near-fatal anaphylaxis 
to a future sting. If one changes the paradigm, to one where 
quality of life is the key driver of venom allergy impact on 
individuals, then the “indications” for VIT change subtly. For 
example, the EAACI recommendation to use VIT for those 
with an urticarial reaction and quality of life impairment 
seems supported, but the AAAAI recommendation that VIT 
is not indicated in those aged #16 years with a cutaneous SR 
to an insect sting may not be appropriate for patients who are 
also suffering significant quality of life impact.
Future perspectives
Ongoing research efforts are studying ways to make VIT 
safer, more convenient, and more widely available without 
compromising treatment efficacy. Table 5 highlights some 
uncertainties that need clarification in future research.
Anti-ige Therapy
The use of omalizumab has been described several time 
during VIT for cases of recurrent anaphylaxis during 
treatment.88,89 It has been shown to have good efficacy in 
improving VIT outcomes in these situations.
SLiT
The benefit of SLIT remains its ease of administration and 
excellent safety profile, which make it suitable for home 
use. Doses used are generally higher than for SCIT, which 
may increase the direct pharmacy cost, but there is a cost 
saving and likely quality of life benefit through reduced 
need for supervised administration of treatment in a medical 
setting.90 An observational study of wasp SLIT in 21 patients 
showed good tolerability and suggested possible efficacy.91 
An observational study of bee venom SLIT suggested 
reduced LLR in the majority of patients treated.92 A single 
randomized controlled trial of SLIT VIT was identified in 
the Cochrane review:19 there was no evidence that SLIT was 
less effective than SCIT for reducing risk of SR or LLR in 
that review, although this preliminary conclusion was based 
on a small number of studies and participants. Given the 
importance of quality of life improvement as an objective 
in VIT, highlighted by the Health Technology Assessment 
Programme (HTA) health economic review70 and the high 
burden of treatment from SCIT regimens, further investiga-
tion of SLIT as a treatment option in insect sting allergy is 
an important goal.
Peptide immunotherapy
Other novel techniques that have been investigated to the ear-
liest level include the use of allergen-derived long synthetic 
peptides to bee venom.93 These injections proved safe and 
instigated T-cell hyporesponsiveness to bee venom allergen. 
There was also a rise in specific IgG4. A small study into 
the use of peptide immunotherapy in mild bee allergy found 
changes in surrogate markers for successful immunotherapy 
were exhibited suggesting that there may be benefit from this 
method of treating bee allergy.94 We are not aware of any 
further studies beyond the late 1990s into peptide immuno-
therapy for venom allergy.
Duration of treatment
The full length of maintenance VIT is often quoted as 
3–5 years, with 5 years showing a better long-term suppres-
sion of risk.80,95 This was initially recommended because the 
SPT or sIgE generally was recorded as negative 3–5 years 
into treatment, and was extrapolated from studies of pollen 
immunotherapy,14,54 though there is debate about whether 
or not a negative intradermal test at the end of treatment is 
the right goal for treatment.80,96 Given the findings above, 
further research is needed to assess long-term quality of 
life in people treated for different durations. Lifelong VIT 
is recommended in some centers for high-risk patients 
Table 5 Key areas of uncertainty for future research
Efficacy of sublingual venom immunotherapy
Optimal duration of venom immunotherapy for prolonged  
treatment effect
The role of sting challenge before or after immunotherapy and effect on 
quality of life
impact of venom immunotherapy in children and adolescents on  
quality of life
Development of improved diagnostics for venom allergy
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such as those with mastocytosis or a baseline tryptase over 
11.4 ng/mL97 due to the significantly higher risk of SRs on 
VIT maintenance and the higher rate of treatment failure. 
However, this is not supported by UK guidelines due to lack 
of evidence.4
The HTA health economic review70 has highlighted the 
importance of quality of life improvement as the primary 
goal of treatment, except in those at high risk of recurrent 
stings such as beekeepers. This means that the duration of 
treatment needs to be a duration which leads to quality of 
life improvement and suggests that 3 years may be adequate 
in all those other than individuals at high risk of recurrent 
reactions. Furthermore, the role of sting challenge as a 
method for providing evidence to patients that they are no 
longer at high risk of sting anaphylaxis merits further inves-
tigation in this context.75,76
Conclusion
Wasp and bee sting allergy can cause rapid-onset fatal 
anaphylaxis. Thankfully, such events are extremely rare; 
however, fear of such an event is a major driver of quality of 
life impairment in people with insect sting allergy. Venom 
anaphylaxis admissions in the UK appear to be increasing 
at a rate of 11.5% (95% CI 10.4–12.7) per year, although 
fatalities remain stable.
VIT is a clinically effective treatment which should be 
offered to those at risk of a SR to an insect sting who have 
significant anxiety or quality of life impairment related to 
fear of future stings. A sting challenge during maintenance 
treatment may enhance the quality of life improvement 
seen with VIT. The decision whether to initiate VIT 
should be largely driven by considerations of quality of 
life impairment rather than an attempt to quantify risk of 
future SR, except in those such as bee keepers who suffer 
frequent stings.
More work is needed to clarify the role of SLIT VIT; the 
role of sting challenges during VIT treatment; the quality 
of life effect of VIT in children and adolescents, and their 
parents; and methods for determining the optimal duration 
of VIT treatment for different patient groups.
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